Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...